Abstract
Background: Doxorubicin is one of the most effective anti-cancer drugs but its use is limited by cumulative cardiotoxicity that restricts lifetime dose. Redox damage is one of the most accepted mechanisms of toxicity, but not fully substantiated. Moreover doxorubicin is not an efficient redox cycling compound due to its low redox potential. Here we used genomic and chemical systems approaches in vivo to investigate the mechanisms of doxorubicin cardiotoxicity, and specifically test the hypothesis of redox cycling mediated cardiotoxicity.
Original language | English |
---|---|
Article number | 12733 |
Pages (from-to) | 1-17 |
Number of pages | 17 |
Journal | PLoS ONE |
Volume | 5 |
Issue number | 9 |
DOIs | |
Publication status | Published - Sept 2010 |
ASJC Scopus subject areas
- General Agricultural and Biological Sciences
- General Biochemistry,Genetics and Molecular Biology
- General Medicine